MetaCap

Xencor Inc. (XNCR)

NASDAQ: XNCRHealth CareBiotechnology: Pharmaceutical PreparationsUSD

33.26-0.75 (-2.21%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

XNCR stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$1.56
52-week range
10.38 – 40.60
Day range
33.12 – 34.27
Volume / Avg
1.22M / 1.54M
Beta
—

52-week range

$10.38$40.60

XNCR stock today

On Nov 20, XNCR ended the session at $33.26, shedding $0.75 (2.21%), versus the S&P 500's 3.70% decline. Shares are 18.1% below their 52-week high of $40.60, set on Nov 11, 2026 and 220.6% above the 52-week low of $10.38, in the middle of the past year's range. XNCR is up 117.2% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 109.6%.

Xencor has posted a net loss over the last twelve months (EPS of -$1.56), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Xencor

Company profile

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn's disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Bassil I. Dahiyat Ph.D.
Headquarters
Pasadena, CA
Employees
260
IPO year
2013
Website
xencor.com

Financial highlights

Full financials

In fiscal 2025, Xencor generated $125.6 million in revenue, up 13.7% from fiscal 2024. Xencor reported a net loss of $91.9 million, compared with a loss of $232.6 million a year earlier. Operating margin was -141.4%.

Xencor annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$125.58M$110.49M$174.62M$164.58M$275.11M
Growth+13.65%-36.72%+6.10%-40.18%+124.23%
Net income$-91.92M$-232.62M$-133.13M$-55.18M$82.63M
EPS (diluted)$-1.24$-3.58$-2.20$-0.93$1.37

Analyst forecast

Forecast

Consensus (14 analysts)

strong_buy

Avg. price target

$42.50+27.78%

  • Strong buy 3
  • Buy 9
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $21.00High $70.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$0.50 vs $-0.35
Surprise
+242.86%

XNCR news

All XNCR news

Xencor peers

Health Care sector
XNCR peer companies
CompanyPrice% ChgMarket capCompare
IDYAIDEAYA Biosciences Inc.25.56-2.33%$2.47Bvs XNCR
MBXMBX Biosciences Inc.49.55-7.23%$2.46Bvs XNCR
ZLABZai Lab Limited ADR21.03-4.06%$2.63Bvs XNCR
PBHPrestige Consumer Healthcare Inc.49.63+0.06%$2.35Bvs XNCR
HCMHUTCHMED (China) Limited ADR13.22-1.71%$2.30Bvs XNCR
RCUSArcus Biosciences Inc.15.62-1.01%$2.25Bvs XNCR
PHVSPharvaris N.V.31.28-1.20%$2.21Bvs XNCR
PRGOPerrigo Company plc15.94-0.62%$2.21Bvs XNCR

Indexes, lists and sector

Xencor stock FAQ

What is Xencor's stock price today?

XNCR last traded at $33.26 as of Nov 20, 4:00 PM EST, down 2.21% on the day. Prices are delayed at least 15 minutes.

Who is Xencor's CEO?

Dr. Bassil I. Dahiyat Ph.D. is the chief executive officer of Xencor Inc., which has about 260 employees.

What is the XNCR 52-week high?

The 52-week high for XNCR is $40.60 and the 52-week low is $10.38. The stock is currently 18.1% below its high.

Compare XNCR